dinoiii
Featured Author
bandwagon supps, i think we will be seeing more and more td's in the near future. whats your take on adding resveratrol to e-form?:box:
Well...this is a climactic switch. Let me talk a bit in stream-of-conscious fashion (I will summarize the basic offering at the end)...
While resveratrol is potentially good candidate for TD delivery systems (i.e. – highly soluble in DMSO; small enough molecular weight – 228.25 DA, etc…), and in vitro offerings when set up against carcinogens of the human oral tissue and/or mouse epidermis may actually support this – it still is a suggestion that doesn’t apply to whole systems.
I have questioned rationale of employment of this agent (by mechanism of action alone) in the past even if it were suitable. While the sirtuin offering to life extension looks promising to insect and other hard exoskeleton phyla, application to humans is hugely off-base and strangely suggested (PGC-1 alpha probably best translation when applying to rodent literature) – yet still remains nothing more than a whim by the great supplement industry “gods.” Perhaps even additionally confounding, DMSO is actually a free-radical scavenger and presents issue with any of these in vitro or epidermal models.
But the fundamental flaw would appear that polyphenolic resveratrol is at the same time an enzymatic inhibitor of oxidative activity if the models are in fact correct to attribute said response to the res molecule in the first place. A transient derivative of resveratrol, resveratrol triphosphate, has been designed to provide a means for the delayed delivery of the active compound in skin tissue where endogenous enzymes capable of dephosphorylation reside. This is something that would need to be inherently overcome for successful administration – something unsolved as far as I have considered the literature to date. There is huge question whether or not bioavailability would be enhanced with TD administration of the pro-molecule rather than resveratrol itself – something no company I am aware of uses to date.
The suggestion of pro-test actions are even further off base though I think bodybuilders would literally “rub anything on themselves” with the promise of test elevation. Yawn! The only thing we have realized with this thought process is that one – we need a boatload of the product (perhaps the pro-molecule would eliminate this need…unsure), and two – estrogen, rather than test elevations are seen to a greater proportion. I believe I have explained the ER-alpha vs. beta distribution (secondary to aryl-hydrocarbon mRNA expression models, which don’t translate cleanly upon critical evaluation) elsewhere on this board which is yet an additional issue and flaw of the compound.
Summary of my stream-of-conscious post: Right now, I don't know that there would be superiority to adding it to Form and it may be irresponsible (or minimally premature) of me to suggest concurrent employment at this time, SO NO. In fact, not only may it cancel out the response to the Form if the estrogenic models are correct (again, it is in-vitro data)...it may also worsen what you are attempting to fend off with the form in the first place (merely direct vs. indirect pathway differential is all).
D_